Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

GSK seeks approval for world's first malaria vaccine

Published 07/24/2014, 06:03 AM
Updated 07/24/2014, 06:20 AM
GSK seeks approval for world's first malaria vaccine

GSK seeks approval for world's first malaria vaccine

LONDON (Reuters) - GlaxoSmithKline (L:GSK) is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.

The British drugmaker said the shot, called RTS,S, is intended exclusively for use outside the European Union but will be evaluated by the European Medicines Agency (EMA) in collaboration with the World Health Organisation (WHO).

Malaria, a mosquito-borne parasitic disease, kills more than 600,000 people a year, mainly babies in the poorest parts of sub-Saharan Africa.

"An effective vaccine for use alongside other measures such as bed nets and anti-malarial medicines would represent an advance in malaria control," GSK said in a statement.

© Reuters. A jogger runs past a signage for pharmaceutical giant GlaxoSmithKline in London

The WHO has previously indicated it may recommend use of RTS,S from as early as 2015 if EMA drugs regulators back its license application.

(Reporting by Kate Kelland, editing by Jason Neely)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.